Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy Efficacy.

Cancer research·2026
Same author

Context-dependent synthetic lethality - an emerging precision therapeutic approach.

Nature reviews. Cancer·2026
Same author

Discovery of INCB191358: A Potent and Selective DGKα/ζ Dual Inhibitor.

Journal of medicinal chemistry·2026
Same author

Discovery of a Selective and Potent Inhibitor of Cyclin-Dependent Kinase 12/13 Employing a Noncovalent Mechanism.

ACS medicinal chemistry letters·2026
Same author

Systematic cysteine scanning identifies a druggable pocket in oncogenic KRAS.

Cell chemical biology·2026
Same author

Enzyme replacement therapy for CLN1 batten disease that crosses the blood-brain-barrier.

Molecular genetics and metabolism·2026

関連する実験動画

Updated: Jun 26, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

癌薬の標的を検証する

John D Benson1, Ying-Nan P Chen, Susan A Cornell-Kennon

  • 1Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.

Nature
|May 26, 2006
PubMed
まとめ
この要約は機械生成です。

がん薬の標的を検証するには,臨床的有効性を実証する必要があります. しかし,初期段階のターゲット検証のための普遍的に受け入れられた基準は,研究を導く上で有用であるにもかかわらず,依然として欠けている.

さらに関連する動画

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

関連する実験動画

Last Updated: Jun 26, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

科学分野:

  • 腫瘍学 腫瘍学
  • 薬理学 薬理学とは
  • バイオメディカル・リサーチ

背景:

  • 癌薬の標的の真の検証は,その標的を介して作用する治療薬の臨床的有効性に依存しています.
  • 薬剤発見投資を導くために,初期段階のターゲット検証は望ましい.
  • 現在の検証研究はがん研究に役立つが,普遍的な基準は欠けている.

研究 の 目的:

  • 癌の初期段階の薬剤標的の検証のコンセプトと望ましいところについて議論する.
  • 目標の検証のための確立された普遍的な基準のギャップを強調する.
  • がん研究における検証結果の重要性を強調する.

主な方法:

  • 薬物標的の検証の原則に関する文献レビューと概念分析.
  • ターゲット検証と臨床薬の開発の関係についての議論.
  • 癌研究における検証基準の現状を分析する.

主要な成果:

  • 臨床的有効性と標的への作用は,がん薬の標的に対する究極の検証指標である.
  • 早期検証は実用的な目標ですが,標準化された普遍的な基準がありません.
  • 既存の検証研究はガイドラインを提供しているが,普遍的に定義されていない.

結論:

  • 早期がん薬標的の検証のための普遍的な基準を定義することは,まだ満たされていないニーズです.
  • 臨床的検証は決定的であるが,早期の指標は効率的な薬剤発見に不可欠である.
  • 標準化された検証方法のさらなる開発は,がん治療の進歩に不可欠です.